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Background: Gamma knife radiosurgery (GKRS) has been increasingly employed for the treatment of elderly
patients with brain metastases, mainly due to its demonstrated effectiveness and low complication rate. However,
only a few studies have investigated the prognostic factors that influence the survival of elderly patients after GKRS.
The purpose of this study was to identify a scoring system that is able to predict the survival of elderly patients
undergoing GKRS using data obtained at the time of diagnosis for brain metastases.
Methods: Between 2004 and 2011, death was confirmed in 147 patients aged 70 years and older who had been treated
with GKRS for brain metastases. Median age at the time of GKRS was 75.7 years (range, 70–86 years). The median tumor
volume was 5.1 cm3 (range, 0.05–59.9 cm3). The median marginal prescription dose was 21.4 Gy (range, 14–25 Gy).
Results: The median survival was 167 days. Overall survival rates at 6 months and 1 year were 60.4% and 29.4%,
respectively. Among the patient characteristics pertaining to systemic cancer and brain metastasis for which data
were obtained preoperatively, a multivariate analysis showed that low Karnofsky performance status (KPS ≤ 80,
P = 0.047) and the presence of extracranial metastases (P = 0.014) detected at the time of brain metastasis diagnosis
were independent prognostic factors for short survival. A high score index for radiosurgery (SIR score≥ 4, P = 0.024)
and a high graded prognostic assessment (GPA score≥ 2, P = 0.004) were associated with longer survival. A multivariate
analysis of the important characteristics of systemic cancer, and the scoring system evaluating survival duration showed
that a low GPA score was the most powerful independent factor for predicting short survival (hazard ratio 1.756, 95%
confidence interval 1.252–2.456, P = 0.001).
Conclusions: GKRS is a safe approach to treat brain metastases in patients age 70 years and older. In this group, our
study identified GPA score at the time of GKRS as a powerful prognostic factor for survival.
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Metastatic brain cancer is almost ten times more com-
mon than a primary malignant brain tumor and 20-40%
of cancer patients will be diagnosed with a metastatic
brain tumor [1]. If these patients are left untreated, the
median survival time is 1–2 months [2], with a 1-year
survival rate of 10.4% [3].* Correspondence: moonks@chonnam.ac.kr
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unless otherwise stated.The incidence of cancer increases with age. In 2000,
12.6–18.1% of the population in developed countries
was over 65 years of age [4]. In South Korea, the crude
incidence rate of cancer development in this age group
is 1,606 cases per 100,000 individuals [5]. However, with
advances in imaging and chemotherapy, the detection
and treatment of cancer, and thus the life expectancy of
elderly cancer patients has improved. Among those
with brain metastases, conventional treatment methods
currently include surgical resection, whole-brain radio-
therapy (WBRT), stereotactic radiosurgery (SRS), or a
combination thereof [6]. However, selection of the mostis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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such as patient’s age, neurologic performance, systemic
disease status, and the size, volume, location, and num-
ber of metastases at presentation [1]. Advanced age is a
poor prognostic factor for survival in patients with
brain metastases [7], and the choice of treatment is
complicated by the fact that elderly patients often have
multiple, concurrent diseases that can restrict their
physiological reserve and physical functioning.
Although WBRT has been generally accepted as a
standard treatment for several decades, accumulated evi-
dence suggests its association with a higher risk of neu-
rocognitive deterioration in elderly patients with brain
metastases [8,9]. Thus, as an alternative approach, gamma
knife radiosurgery (GKRS) has gained increasing favor as
the primary treatment modality [10]. The purpose of this
study was to identify a scoring system able to predict sur-
vival outcome in patients age 70 years and older who
underwent GKRS for brain metastases. The predictive
power of four different scoring systems was evaluated:
graded prognostic assessment (GPA), recursive portioning
analysis (RPA), the score index for radiosurgery (SIR), and
the basic score for brain metastases (BSBM) [11-15].
Methods
Patients
The study was conducted in compliance with the Declar-
ation of Helsinki (sixth revision, 2008), and fulfilled all of
the requirements for patient anonymity. This study was ap-
proved by the Institutional Review Board of the Chonnam
National University Hwasun Hospital (CNUHH-2014-31).
A database of patients with brain tumors treated at our in-
stitution was used to identify the 1174 patients with brain
metastasis who underwent GKRS between May 2004 and
December 2013. From this group, the 320 patients older
than 70 years of age were selected and their data were
reviewed. Patients previously treated with WBRT were ex-
cluded from this study. Among the included patients, there
were 147 confirmed deaths. These patients were the focus
of this study.
Analysis variables
The clinical and radiological data of the patients at the
time of diagnosis of brain metastasis were collected.
Clinical data included age, sex, presenting symptoms,
time interval between the diagnosis of primary cancer
and brain metastasis, Karnofsky performance status (KPS),
and survival time. Radiological data included the presence
of extracranial metastasis, the status of the primary cancer,
the number and location of brain lesions, the size or
volume of the largest brain lesion, and concomitant intra-
tumoral hemorrhagic changes. Based on both sets of data,
RPA, GPA, SIR, and BSBM scores were calculated. The
RPA classification assigns patients with brain metastasesto one of three classes that predict survival [15]: Class I
patients are those with a KPS ≥ 70 at an age < 65 years
with controlled primary disease and no evidence of extra-
cranial metastases. Class III patients have a KPS < 70.
Class II patients are those who do not fit into classes I or
III. The GPA classification considers age, KPS, the pres-
ence of extracranial metastases, and the number of brain
metastases [13]. The SIR uses a system of seven grades to
determine prognosis based on age, KPS, primary cancer
status, number of brain metastases, and volume of the lar-
gest brain metastasis [12]. The parameters of the BSBM
classification are the KPS, primary cancer status, and the
presence of extracranial metastases [14]. The features of
the scoring systems used in this study are summarized in
Table 1.
GKRS protocol for brain metastasis
GKRS, performed using the Leksell Gamma Knife
(model C or Perfexion, Elekta AB, Stockholm, Sweden),
was used to treat 455 lesions in the 147 patients in-
cluded in this study. The median maximal dose was
37 Gy (range, 18–62.5 Gy), with a median marginal
tumor dose of 21 Gy (range, 14–25 Gy) at the 40–85%
isodose line.
Statistical analysis
Overall survival (OS) was defined as the time between
the dates of brain metastasis diagnosis until death. The
probability of OS was analyzed according to the Kaplan-
Meier method, and the resulting values were compared
using log-rank tests. Factors considered to be predictive
of OS were analyzed using a multivariate logistic regres-
sion model. All of the statistical analyses were performed
using SPSS version 20.0 for Windows (SPSS, Chicago,
IL, USA); P < 0.05 considered statistically significant.
Results
Patient characteristics
The clinicoradiological characteristics of the enrolled pa-
tients are summarized in Table 2. The most common
presenting symptoms were motor/sensory deficits, head-
ache, and dizziness. Major neurological symptoms, such
as sensory/motor deficit, deterioration of mental status,
gait disturbance, or swallowing difficulty, were detected
in 53 patients (36.1%). The primary cancer site was the
lung (n = 111, non-small-cell lung cancer in 93 patients
and small-cell lung cancer in 18 patients). The median
time between the diagnosis of primary cancer and that
of brain metastasis was 11.4 months (range, 0–106
months). Brain metastases were synchronously (within
3 months after the diagnosis of the primary cancer) de-
tected in 65 patients (44.2%).
The enrolled patients were grouped using the four
scoring or classification systems evaluated in this study
Table 1 Prognostic scoring systems (GPA, SIR, BSBM)
GPA score SIR score BSBM score
0 0.5 1 0 1 2 0 1
Age ≥60 51-59 ≤50 ≥60 51-59 ≤50 NA
KPS <70 70-80 90-100 ≤50 60-70 >70 50-70 80-100
Control of primary cancer NA PD PR-SD CR-NED No Yes
Volume of the largest BM (cc) NA >13 5-13 <5 NA
No. of BM >3 2-3 1 ≥3 2 1 NA
EC metastasis (+) (−) NA (+) (−)
BM; brain metastasis, CR; complete regression, EC; extracranial, KPS; Karnofsky performance status, NA; not available, NED; no evidence of disease, No.; number,
PD; progression disease, PR; partial regression, SD; stable disease.
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126 patients (85.7%) were assigned to class II, and the
remaining 21 patients were assigned to class III. In the
SIR system, 93 patients (63.3%) had a score of 3–5, 22
patients (15.0%) had a score of 1 or 2, and 32 patients
(21.8%) had a score > 6. These patients were subse-
quently classified into low (score 1–3, n = 42) and high
(score ≥ 4, n = 105) SIR groups. In the GPA scoring sys-
tem, 18 patients (12.2%) had a score < 1, 59 (40.1%) had
a score between 1 and 2, and the remaining 70 (47.6%)
had a score ≥ 2. These patients were thus classified into
low (score < 2, n = 77) and high (score ≥ 2, n = 70) GPA
groups. In the BSBM scoring system, the majority of the
patients had a score of 2 (49.7%) or 1 (35.6%); the
remaining patients had a score of 0 (4.1%) or 3 (10.9%).
These patients were classified into low (score 0–1, n = 58)
and high (score 2–3, n = 89) BSBM groups.
Overall survival and prognostic factors
The median OS of the 147 patients who eventually died
after GKRS was 167 days (95% confidence interval [CI]:
108.4–225.6 days, Figure 1). The OS rates at 6 months
and 1 year were 60.4% and 29.4%, respectively. The
cause of death in 120 patients was progressive systemic
cancer or related complications (e.g., acute respiratory
failure, hepatic failure); 18 patients died as a conse-
quence of brain metastases; and 5 patients died from
factors not associated with systemic cancer or brain me-
tastasis, including suicide and myocardial or cerebral in-
farction. In the remaining four patients the cause of
death was not specified.
The results of statistical analyses of several characteris-
tics of systemic cancer and brain metastasis possibly as-
sociated with survival time are summarized in Table 3.
KPS (Figure 2, left), primary cancer type, and extracranial
metastasis (Figure 2, right) showed statistical significance
in univariate analysis. Of these, KPS and extracranial
metastasis were also statistically significant in the multi-
variate analysis. In addition, a definitive relationship be-
tween survival duration after GKRS and the SIR andGPA scores at the time of diagnosis for brain metastasis
was determined (Table 3 and Figure 3). Patients with a
high SIR score (≥4) had a significantly longer survival
time than patients with a low SIR score, as shown in
univariate analysis (209 ± 24.7 days vs. 130 ± 7.0 days,
P = 0.024; Figure 3, lower). In fact, the duration of sur-
vival increased with an increasing SIR score (median
survival time of 65, 129, 152, 171, 174, 210, and 373 days
for scores of 1–7, respectively, P = 0.004). Within the
GPA scoring system, patients with a high GPA score
(≥2) survived longer than those with a low GPA score
(213 ± 22.0 days vs. 128 ± 14.9 days, P = 0.001; Figure 3,
upper), and GPA score correlated positively with sur-
vival duration (median survival time of 65, 129, 171,
107, 234, 143, 167 for a score of 0, 0.5, 1.0, 1.5, 2.0, 2.5,
and 3.0, respectively, P = 0.002).
Multivariate analysis of the important characteristics of
systemic cancer with respect to the four scoring systems
assessing survival duration identified low GPA score as the
most powerful independent factor of short survival (hazard
ratio 1.756, 95% CI 1.252–2.456, P = 0.001, Table 4).
Prognostic factors favoring longer survival after
sequential systemic chemotherapy
Considering the morbidity and side effects associated
with chemotherapy in elderly patients, and especially
those with terminal cancer, in this study it was import-
ant to identify the prognostic factors favoring longer sur-
vival after sequential systemic chemotherapy following
GKRS. However, among the patients analyzed in this
work, sequential chemotherapy for systemic cancer after
GKRS did not confer a survival benefit (212 ± 26.5 days
vs. 143 ± 18.7 days in non-treated patients, P = 0.257) re-
gardless of the prognostic variable or scoring system
used in the analysis (data not shown).
Discussion
A cross-national comparison performed in 2000 showed
that the proportion of individuals age ≥ 65 years was
12.6 to 18.1% [4], with the proportion predicted to reach
Table 2 Summary of tumor characteristics and treatment
parameters
Parameter No. (%)
Characteristics of systemic course





Median (range) 75.6 (70–86)
70 - 75 80 (54.4%)
>75 67 (45.6%)
Signs and symptoms
Mental status change 10 (6.8%)
Dizziness 12 (8.2%)
Motor/sensory deficit 40 (27.3%)
Gait disturbance 1 (0.7%)
Headache 27 (18.3%)
Nausea & vomiting 2 (1.3%)
Swallowing difficulty 2 (1.3%)
Incidental detect 53 (36.1%)
Karnofsky Performance Status (KPS)





Lung cancer 111 (75.5%)
Rectal cancer 7 (4.7%)
Colon cancer 6 (4.0%)
Gastric cancer 3 (2.0%)
Breast cancer 6 (4.0%)
Cervix cancer 1 (0.6%)
Gall bladder cancer 2 (1.2%)
Hepatic cancer 1 (0.6%)
Renal cancer 2 (1.2%)
Pancreas cancer 1 (0.6%)
Melanoma 2 (1.2%)
Prostate cancer 1 (0.6%)
Esophageal cancer 1 (0.6%)
Not confirmed 3 (2.0%)
Primary cancer status
Progression disease 102 (69.4%)
Stable, partial regression 40 (27.2%)
Complete regression 5 (3.4%)










Median (range) 2.0 (1–12)
Single 61 (41.5%)
2 - 5 58 (39.5%)
>6 28 (19.0%)
Largest lesion volume (cc)

















0 - 3 42 (28.6%)
4 - 7 105 (71.4%)
GPA score
Median 1.5
0 - 1.5 77 (52.4%)





0 - 1 58 (39.5%)
2 - 3 89 (60.5%)
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Figure 1 Overall survival (OS) of 147 elderly patients with brain metastases. Median OS was 167 days (95% CI: 108.4–225.6). The survival
time of 53.1% of the patients was 0.5 years; in 20.4% it was 1 year, and in 1% it was 2 years.
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older population, the incidence of brain metastasis in
elderly patients diagnosed with cancer has been rising
for several reasons, including the longer survival of pa-
tients with a previously diagnosed localized cancer, and
the improved detection of metastatic tumors by more
sensitive imaging techniques. Nonetheless, in the majority
of patients with malignant primary or metastatic brain
tumors, age is an important prognostic factor [15,17].
For several decades, WBRT was the treatment of
choice for metastatic brain tumors [18]. However, its use
in elderly patients was hindered by impaired postopera-
tive functional or cognitive status [9] and poor social
services support [19,20] of treated patients. Moreover,
although the prophylactic role of WBRT in some cancers
has been demonstrated [21], prolonged treatment dur-
ation with multiple fractions may not be possible in
elderly patients. In a comparison of SRS and WBRT, pa-
tients receiving SRS had better OS rates [22]. The pre-
ferred use of SRS is that it achieves repeated control of
the target lesion without risk of detrimental neurocogni-
tive effects after the therapy [8,23]. Because of its few
side effects, GKRS is an excellent treatment option for
patients with metastatic brain tumors, including elderly
patients. Other advantages of GKRS are that it is minim-
ally invasive, substantially reduces hospitalization time,is relatively inexpensive, and is associated with minimal
pain and post-treatment complications [24].
Well-known prognostic scoring systems used to assess
patients treated with GKRS for brain metastases are
RPA, SIR, BSBM, and GPA, which were created from
databases containing 65–1200 patients with brain metas-
tases from a variety of primary tumors [12-15]. GPA was
developed to address the limitations of the three other
scoring systems; specifically, RPA and BSBM do not con-
sider the number of metastases; RPA, BSBM, and SIR re-
quire estimation of the degree of control of the systemic
disease, including a primary malignancy, which leads to
inconsistencies due to variation in the type and timing
of imaging tests. The SIR takes into account treatment
factors, such as the volume of the largest lesion at the
time of radiosurgery, to predict outcome before treat-
ment decisions are made [25-27]. In the GPA, compo-
nents of the other scoring systems that are difficult to
quantify, such as the control of extracranial disease, were
removed as part of the general removal of treatment-
related factors such that treatment choice rather than
treatment result was reflected [26,27]. The GPA system
considers different combinations of diagnosis-specific
prognostic factors, and thus better predicts the outcome
that can be expected in elderly patients treated with
various therapeutic options [28]. The KPS is included in





Univariate analysis Multivariate analysis
P value HR 95% CI P value
Characteristics of systemic cancer
Sex 0.115 ND 0.259
Female 39 212 ± 86.8
Male 108 156 ± 26.4
Age 0.780 ND 0.554
70 - 75 80 199 ± 26.3
≥75 67 130 ± 23.5
KPS 0.047 1.539 1.089-2.173 0.014
≤80 62 125 ± 19.7
≥90 85 199 ± 21.2
Origin cancer 0.032 ND 0.070
Lung 117 171 ± 27.9
Non-lung or ND 30 110 ± 20.5
Primary cancer status 0.488 ND 0.980
Non-PD 45 171 ± 27.6
PD 102 141 ± 32.1
Extracranial metastasis 0.032 0.633 0.445-0.900 0.011
No 56 189 ± 35.5
Yes 91 141 ± 19.9
Characteristics of brain metastasis
Presentation type 0.289 ND 0.646
Synchronous 65 141 ± 21.1
Metachronous 82 188 ± 26.3
Number of metastasis 0.247 ND 0.235
Single 61 209 ± 25.7
Multiple 86 141 ± 17.7
Volume of the largest lesion (cc) 0.179 ND 0.410
<13 126 167 ± 30.1
≥13 21 171 ± 59.5
Infratentorial/brainstem involvement 0.411 ND 0.363
No 95 156 ± 26.1
Yes 52 188 ± 42.7
Sequential systemic chemotherapy 0.257 ND 0.148
No 92 143 ± 18.7
Yes 55 212 ± 26.5
Scoring system
RPA class 0.613 NA
II 126 167 ± 30.5
III 21 170 ± 58.7
SIR score 0.024 NA
Low (1–3) 42 130 ± 7.0
High (4–7) 105 209 ± 24.7
Park et al. BMC Cancer  (2015) 15:54 Page 6 of 9
Table 3 Univariateand multivariate analyses for survival predictors in the elderly with brain metastasis after GKRS
(Continued)
GPA score 0.001 NA
Low (0–1.5) 77 128 ± 14.9
High (2–4) 70 213 ± 22.0
BSBM score 0.273 NA
Low (0–1) 58 141 ± 17.1
High (2–3) 89 207 ± 21.7
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geting elderly patients, it was shown to be the strongest
predictor of prognosis [11].
To identify prognostic factors specific for elderly pa-
tients, it is necessary to examine their clinically based
prognostic scores and then compare those values with
other prognostic scores. Minniti et al. [7] reported that
patients with a KPS > 70 and stable extracranial disease
had significantly longer survival. Kim et al. [29] found
that survival was significantly influenced by the number
of brain metastases at the time of SRS, and the primary
lung tumor type of the patients. However, while these
studies identified KPS, extracranial disease, and the
number of brain metastases as significant factors for sur-
vival, they did not specify which scoring system most ac-
curately predicted survival in elderly patients with brain
metastasis treated with GKRS. A recent report suggestedFigure 2 Kaplan-Meier analyses of overall survival for the 147 study p
estimated using a log-rank test). Left: Survival curve for KPS, Right: Survivthe use of the modified RPA to select favorable candi-
dates for GKRS, even among patients age 80 years and
older [30]. In our study, KPS ≥ 90 and no extracranial
metastasis at the time of brain-metastasis diagnosis were
the most important factors predicting survival. Although
in the multivariate analysis both the GPA score and the
SIR were statistically significant in predicting survival,
the GPA score may be the more powerful independent
prognostic factor because it takes into account both the
KPS and the presence of extracranial metastasis. Many
oncologists and neurosurgeons may hesitate to recom-
mend aggressive treatment for brain metastasis in elderly
cancer patients. The results of this and previous studies
support the use of GKRS in patients age 70 years and
older and even in those 80 years and older. However, al-
though chemotherapy for primary cancer increased the
survival of elderly patients according to some studiesatients according to different predictors (overall comparison was
al curve for extracranial metastasis.
Figure 3 Kaplan-Meier analyses of overall survival for the 147 study patients according to the different scoring systems (overall comparison
was estimated using a log-rank test). Upper: Survival curve for GPS, Lower: Survival curve for SIR.
Table 4 Multivariate analysis for prognostic factors
Prognostic factors Multivariate analysis
HR 95% CI P value
Male ND 0.679
≥75 yrs ND 0.200
KPS≤80 ND 0.223
Non-lung origin ND 0.073
Presence of extracranial metastasis ND 0.646
Low SIR score (<4) ND 0.282
Low GPA score (<2) 1.756 1.252-2.456 0.001
Park et al. BMC Cancer  (2015) 15:54 Page 8 of 9[31], in our series there were no significant differences
between GKRS and GKRS followed by chemotherapy.
Conclusions
This study was based on a retrospective investigation; thus,
selection bias due to missed cases was a possibility. Add-
itionally, there was no information on the quality of life or
the control of treated lesions in patients who underwent
GKRS. Nevertheless, our results identified extracranial me-
tastases and KPS as independent prognostic factors for sur-
vival in elderly patients with brain metastasis treated with
GKRS. Among the scoring systems analyzed in this study,
the GPA was the most powerful and most specific prognos-
tic scoring system. These are important considerations that
influence treatment choice and patient outcome and should
be taken into account in therapeutic decision-making.
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